EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%

Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1...

詳細記述

保存先:
書誌詳細
出版年:Respir Med Case Rep
主要な著者: Zarogoulidis, Paul, Chinelis, Panos, Efthymiou, Christofors, Athanasiadou, Anastasia, Mpikos, Vasilis, Papatsibas, George, Papadopoulos, Vasilis, Maragouli, Elena, Huang, Haidong, Trakada, Georgia, Kallianos, Anastasios, Veletza, Lemonia, Hohenforst-Schmidt, Wolfgang
フォーマット: Artigo
言語:Inglês
出版事項: Elsevier 2017
主題:
Case Report
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5524632/
https://ncbi.nlm.nih.gov/pubmed/28761805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.05.010
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料